1. Home
  2. FGEN vs GDTC Comparison

FGEN vs GDTC Comparison

Compare FGEN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • GDTC
  • Stock Information
  • Founded
  • FGEN 1993
  • GDTC 2018
  • Country
  • FGEN United States
  • GDTC Singapore
  • Employees
  • FGEN N/A
  • GDTC N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGEN Health Care
  • GDTC Health Care
  • Exchange
  • FGEN Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • FGEN 34.5M
  • GDTC 29.4M
  • IPO Year
  • FGEN 2014
  • GDTC 2023
  • Fundamental
  • Price
  • FGEN $0.46
  • GDTC $2.65
  • Analyst Decision
  • FGEN
  • GDTC Buy
  • Analyst Count
  • FGEN 0
  • GDTC 1
  • Target Price
  • FGEN N/A
  • GDTC $5.00
  • AVG Volume (30 Days)
  • FGEN 727.9K
  • GDTC 25.0K
  • Earning Date
  • FGEN 02-24-2025
  • GDTC 01-01-0001
  • Dividend Yield
  • FGEN N/A
  • GDTC N/A
  • EPS Growth
  • FGEN N/A
  • GDTC N/A
  • EPS
  • FGEN N/A
  • GDTC N/A
  • Revenue
  • FGEN $180,015,000.00
  • GDTC $330,254.00
  • Revenue This Year
  • FGEN $21.91
  • GDTC $14.71
  • Revenue Next Year
  • FGEN N/A
  • GDTC N/A
  • P/E Ratio
  • FGEN N/A
  • GDTC N/A
  • Revenue Growth
  • FGEN 16.15
  • GDTC N/A
  • 52 Week Low
  • FGEN $0.18
  • GDTC $1.20
  • 52 Week High
  • FGEN $2.80
  • GDTC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 41.72
  • GDTC 49.22
  • Support Level
  • FGEN $0.46
  • GDTC $2.55
  • Resistance Level
  • FGEN $0.51
  • GDTC $2.94
  • Average True Range (ATR)
  • FGEN 0.04
  • GDTC 0.22
  • MACD
  • FGEN -0.01
  • GDTC 0.01
  • Stochastic Oscillator
  • FGEN 6.59
  • GDTC 53.23

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: